Advertisement
Screener

PASITHEA THERAPEUTICS CORP. (KTTA) Income (Loss) from Continuing Operations, Per Basic Share

2.8 / 5 stars · 68/120 Roast Me

PASITHEA THERAPEUTICS CORP. Income (Loss) from Continuing Operations, Per Basic Share

PASITHEA THERAPEUTICS CORP. (KTTA) reported Income (Loss) from Continuing Operations, Per Basic Share of -$12.69 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2025-03-24

  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for the quarter ending 2024-09-30 was -$2.87.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for the quarter ending 2024-06-30 was -$3.71.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for the quarter ending 2024-03-31 was -$3.70.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for the quarter ending 2023-09-30 was -$2.87.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for fiscal 2024 was -$12.69.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for fiscal 2023 was -$12.64.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, per basic share for fiscal 2022 was -$9.29.
Period endIncome (Loss) from Continuing Operations, Per Basic Share 3 monthIncome (Loss) from Continuing Operations, Per Basic Share 3 month as first filedIncome (Loss) from Continuing Operations, Per Basic Share 6 monthIncome (Loss) from Continuing Operations, Per Basic Share 6 month as first filedIncome (Loss) from Continuing Operations, Per Basic Share 9 monthIncome (Loss) from Continuing Operations, Per Basic Share 9 month as first filedIncome (Loss) from Continuing Operations, Per Basic Share 12 month
2024-12-31-$12.69
10-K · filed 2025-03-24
2024-09-30-$2.87
10-Q · filed 2024-11-13
-$10.28
10-Q · filed 2024-11-13
2024-06-30-$3.71
10-Q · filed 2024-08-13
-$7.41
10-Q · filed 2024-08-13
2024-03-31-$3.70
10-Q · filed 2024-05-14
2023-12-31-$12.64
10-K · filed 2025-03-24
2023-09-30-$2.87
10-Q · filed 2024-11-13
-$0.14
10-Q · filed 2023-11-13
-$8.13
10-Q · filed 2024-11-13
-$0.41
10-Q · filed 2023-11-13
2023-06-30-$2.75
10-Q · filed 2024-08-13
-$0.14
10-Q · filed 2023-08-11
-$5.26
10-Q · filed 2024-08-13
-$0.26
10-Q · filed 2023-08-11
2023-03-31-$2.60
10-Q · filed 2024-05-14
-$0.13
10-Q · filed 2023-05-12
2022-12-31-$9.29
10-K · filed 2024-03-29
2022-09-30-$0.16
10-Q · filed 2023-11-13
-$0.31
10-Q · filed 2023-11-13
2022-06-30-$0.09
10-Q · filed 2023-08-11
-$0.15
10-Q · filed 2023-08-11
2022-03-31-$0.06
10-Q · filed 2023-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Rocket One Inc. (RKTO)United States$0.019B